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Introduction 
 
Acute renal failure (ARF) occurs when there is a 
rapid loss of the clearance capacity of the kidney.  
This leads to an abrupt accumulation of unexcreted 
waste products. Even though the specificity of uremic 
toxins is debated, it is clear that accumulated waste 
products lead to anorexia, lethargy, nausea, vomiting 
and other symptoms associated with uremia. ARF 
also causes accumulation of sodium, water and 
electrolytes which can cause life-threatening 
problems from extracellular volume overload, 
hyperkalemia, etc. 
In patients with ARF, the mortality rate has not 
changed substantially in spite of the intensive use of 
dialysis. For example, the mortality rate of wounded 
soldiers with ARF in the Korean and Viet Nam wars 
was scarcely different in spite of the wide-spread 
availability of dialysis in Viet Nam compared to the 
Korean War [1]. Even patients who develop ARF 
from other causes have a poor prognosis with a 
mortality rate of 50-60%. The rate is even higher in 
elderly patients and those with failure of other organs 
[2]. 
Why the mortality rate is so high if dialysis can 
replace the function of the kidney as it does for          
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patients with chronic renal failure (CRF)?  There is 
no simple answer but one reason is the catabolism 
associated with ARF or diseases causing ARF.  
Secondly, ARF develops rapidly, so metabolic 
defects are more dramatic and the ability of a patient 
to respond to metabolic abnormalities is more limited 
than in CRF patients. Consequently, principles 
guiding the therapy of metabolic abnormalities 
associated with CRF may not apply to patients with 
ARF.  
It is important to recognize this difference because it 
changes the dietary prescription, including the 
amounts of protein and calories (fat and 
carbohydrates), as well as minerals and vitamins.  
 
Metabolic abnormalities in ARF 
 
Energy metabolism 
 
In rats with experimental ARF but without sepsis, 
trauma, etc. there is decreased oxygen consumption 
(i.e. "uremic hypometabolism") even when hypother-
mia and acidosis are corrected, suggesting 
impairment of oxidative phosphorylation [3,4]. In 
adults with ARF or advanced CRF, energy 
expenditure is normal unless there is a complicating 
disease [5,6]. These results indicate that acute uremia 
exerts little influence on energy metabolism and 
decreases rather than augments energy expenditure. 
This observation is consistent with the grossly 
abnormal pattern of substrate oxidation in ARF. 
Carbohydrate oxidation is slightly reduced and lipid 
oxidation slightly increased in subjects with ARF 
after an overnight fast. 
 
Carbohydrate metabolism 
 
ARF is commonly associated with hyperglycemia 
because of insulin resistance. In experimental ARF, 
the plasma insulin concentration is elevated, maximal 
insulin-stimulated glucose uptake by skeletal muscle 
is 50% lower and glycogen synthesis in muscle is 
impaired [7,8]. Since the dose-response relationship 
between insulin concentration and glucose uptake 
reveals that the insulin concentration causing a half-
maximal stimulation of glucose uptake is normal, 
there must be a postreceptor defect in insulin action 
rather than impaired insulin sensitivity in ARF.  In 
support of this conclusion, the maximal rate of 
insulin-stimulated glycogen synthesis in muscle is 
abnormally low [8]. 
A second abnormality in glucose metabolism in ARF 
is accelerated hepatic gluconeogenesis mainly from 
amino acids released during muscle protein 
catabolism. Hepatic extraction of amino acids, their 
conversion to glucose and urea production are all 
increased by ARF [9,10]. 
The abnormality in muscle glucose and protein 
metabolism caused by ARF were shown to be 
interrelated: the impaired uptake of glucose and its 
conversion to energy in muscle are highly correlated 
with the accelerated rate of protein catabolism [7,8]. 
In healthy subjects, hepatic gluconeogenesis from 
amino acids is readily and completely suppressed by 
an exogenous infusion of glucose which stimulates 
release of insulin. However, in conditions such as 
sepsis or ARF, hepatic glucose formation is 
diminished but not halted by infusing glucose.  This 
has important implications for prescribing a regimen 
of nutritional support for an ARF patient because it 
means that protein catabolism cannot be suppressed 
simply by providing increased amounts of nutritional 
substrates [11]. To improve therapy of ARF patients 
and preserve lean body mass, strategies that 
successfully block protein catabolism must be 
developed. 
 
Lipid metabolism 
 
There are profound alterations in lipid metabolism in 
patients with ARF. The triglyceride content of 
plasma lipoproteins, especially VLDL and LDL, is 
increased but total cholesterol, and in particular, 
HDL-cholesterol are decreased [5]. The protein 
component of lipoproteins also is abnormal with low 
concentra-tions of apoproteins A-I and A-II [12]. The 
major cause of these lipid abnormalities is impaired 
lipol-ysis. In ARF patients, the activities of both 
lipolytic pathways (peripheral lipoprotein lipase and 
hepatic triglyceride lipase), are decreased by ~ 50%. 
These findings are important for the design of 
nutritional regimens. For example, lipids contained in 
the lipid emulsions used in parenteral nutrition 
regimens are degraded in the same fashion as the 
endogenous VLDL lipid particles.  Consequently, the 
impaired lipolysis caused by ARF delays the 
elimination of intravenously infused lipid emulsions; 
the elimination half-life is doubled and the clearance 
of conventional fat emulsions is reduced by more 
than 50% [12]. 
Lipid emulsions used in parenteral nutrition usually 
contain triglycerides with long-chain fatty acids, 
mostly derived from soybean oil, but there are fat 
emulsions with a mixture of long-and medium-chain 
triglycerides. The proposed advantages of infusing 
medium-chain triglycerides include:  
 A more rapid elimination of lipids from the 
plasma due to a higher affinity of the medium-
chain triglycerides for lipoprotein lipase.  
 A carnitine-independent metabolism of fatty 
acids.  
However, the impaired lipolysis caused by ARF 
cannot be bypassed simply by using medium-chain 
triglycerides; the clearance of this type of fat 
emulsion is equally retarded in ARF patients [12]. In 
contrast, the oxidation of fatty acids is not impaired 
by ARF. 
The abnormalities in lipid metabolism associated 
with ARF are not due to carnitine deficiency. In 
contrast to patients with CRF, plasma carnitine levels 
are increased in ARF due to an increased release of 
carnitine from muscle plus activated carnitine 
synthesis in the liver.  
 
Protein-and amino acid metabolism 
   
A major problem of ARF is the rapid accumulation of 
nitrogen-containing waste products. A major cause of 
this problem is excessive protein catabolism with 
sustained negative nitrogen balance [5]. The import-
ance of abnormal protein metabolism caused by ARF 
is highlighted by considering normal values of 
protein turnover in adults (Figure 1). In a 70 kg man 
eating 1 g protein/kg/day (protein is 16% nitrogen), 
the nitrogen excretion is 11.2 g/day if the patient is in 
neutral nitrogen balance. The amount of protein 
being synthesized and degraded each day is about 
280 g protein/day [11].   
In fact, it is about 10-fold higher than the amounts of 
plasma proteins being synthesized and degraded each 
day. These results emphasize why a small, but 
persistent decrease in the rate of protein synthesis or 
increase in the rate of protein degradation cause large 
losses of lean body mass. Experimentally, it has been 
shown that ARF causes muscle protein catabolism by 
reducing the rate of protein synthesis and increasing 
the rate of protein degradation. The abnormalities in 
protein synthesis and breakdown in muscle cause 
excessive release of amino acids from muscle which
 
 
 
 
Fig. 1. Rate of protein turnover in a normal 70 kg man eating 1 g protein / kg / day. 
 
 
 
are metabolized to urea and other nitrogen-containing 
waste products [7,13]. 
Besides abnormalities in protein turnover, uremia can 
blunt the transport of amino acids into muscle and 
increase the degradation of amino acids in muscle.  In 
rats with ARF, there is depressed transport of amino 
acids into skeletal muscle because the activity of the 
System A transporter is blunted[14]. The abnormality 
in amino acid transport is linked to insulin resistance 
and to impaired cellular ion transport processes, 
including depressed sodium-coupled amino acid 
transport. This problem is linked to impaired NaK-
ATPase activity [15,16]. We found that both the 
activity and receptor density of NaK-ATPase are 
abnormal in adipose cells and muscle from uremic 
rats apparently because there is a circulating inhibitor 
since there is no consistent abnormality in expression 
of NaK-ATPase in muscle or adipose cells [16,17]. 
ARF patients with metabolic acidosis also exhibit 
accelerated degradation of amino acids [18,19]. One 
mechanism for this abnormality was shown to be an 
increase in the activity of the rate-limiting enzyme in 
branched-chain amino acid (BCAA) metabolism, 
branched-chain ketoacid dehydrogenase or BCKAD 
[20,21]. When accelerated amino acid catabolism is 
combined with reduced amino acid uptake and 
impaired protein synthesis, the pools of amino acids 
in plasma and in the intracellular compartment 
become imbalanced and this leads to changes in 
plasma amino acids.  Any change in plasma amino 
acids will be aggravated when there is an inadequate 
intake of protein or amino acids because of ARF.  
The major consequence of abnormalities in amino 
acid metabolism is that amino acids are redistributed 
to the liver: hepatic extraction of amino acids from 
blood, with resulting gluconeogenesis, ureagenesis 
and protein synthesis (acute phase protein secretion) 
all are increased in the liver of rats with ARF [9,10].  
In summary, there are multiple abnormalities of 
protein and amino acid metabolism in uremia. 
 
Causes of muscle catabolism in ARF 
 
In ARF, there are stimuli that could accelerate protein 
and amino acid catabolism, including defects in 
hormonal responses and metabolic acidosis. For 
example, a major catabolic stimulus in ARF is the 
resistance of muscle to the anabolic effects of insulin.  
In experimental ARF, it was found that the maximal 
rate of insulin-stimulated protein synthesis in muscle 
is depressed while the rate of protein degradation in 
muscle is increased even in the presence of insulin 
[7]. As noted, ARF-induced abnormalities in protein 
and energy metabolism in muscle are linked; the rate 
of protein catabolism was found to be closely related 
to the decrease in glucose uptake and its conversion 
to lactate in muscle [7,8]. 
Besides insulin resistance in ARF, there are high 
circulating levels of catabolic hormones (glucocor-
ticoids, catecholamines, glucagon) in blood and 
hyperparathyroidism may be present [5]. Each of 
these could stimulate protein breakdown. For 
example, increased glucocorticoids will reduce 
protein synthesis and increase protein degradation in 
muscle [22,23]. It also is possible that release of 
inflammatory mediators (e.g., tumor necrosis factor 
and interleukins) because of sepsis or other diseases 
causing ARF act to stimulate muscle hypercatabolism 
[11]. Inadequate nutritional support in the presence of 
these stimuli will potentiate the loss of lean body 
mass.  
Metabolic acidosis also stimulates protein breakdown 
in muscle [24,25]. In adults with uncomplicated 
metabolic acidosis or with the acidosis of uremia, 
there is increased catabolism of protein and BCAA 
[18,19]. Other reports document that acidosis 
stimulates protein catabolism in children and adults, 
including dialysis patients [26,27]. It is important to 
emphasize that the catabolism caused by metabolic 
acidosis will be most dramatic in patients with 
anorexia or those eating a low-protein diet.This 
occurs because metabolic acidosis impairs the normal 
responses to eating a low-protein diet (Figure 2). 
 
 
 
Fig. 2. The metabolic responses to changes in dietary protein are a 
progressive decrease in amino acid oxidation until the minimum 
daily requirement (MDR) of ~ 0.6 g protein/kg/day is reached.  At 
this level, protein degradation becomes lower. 
 
Results depicted in Figure 2 show that when dietary 
protein is restricted, the principal compensatory 
response is a dramatic reduction in amino acid 
oxidation resulting in more efficient utilization of 
dietary essential amino acids. If protein intake is 
adequate, production of metabolic waste products is 
decreased and nitrogen balance is neutral. This 
response permits the body to retain enough amino 
acids to replace the protein lost in normal turnover 
without changing the levels of amino acids in plasma 
and cells [11]. If, however, dietary protein is below 
the minimum daily amount (~ 0.6 g protein/kg/day), 
another response is activated and the rate of protein 
degradation falls. Fortunately, renal failure alone, in 
the absence of metabolic acidosis, does not block 
these responses [28,29]. Metabolic acidosis, however, 
stimulates both the degradation of BCAA by 
activating BCKAD and the rate of protein 
degradation in muscle [18-21,24,25]. Consequently, 
metabolic acidosis would block the ability of the 
patient to respond to a low-protein diet by reducing 
the rate of degradation of amino acids and protein.  
This would lead to negative nitrogen balance and loss 
of lean body mass. 
Another stimulus for catabolism is dialysis. Protein 
catabolism during dialysis is due in part to losses of 
nutritional substrates [30]. There is also evidence that 
the dialytic process stimulates protein degradation in 
muscle, even in normal subjects [31]. In these 
experiments, normal adults were given a "sham-
dialysis" by passing their blood through a dialysis 
filter while the rate of protein degradation was 
measured in leg muscles. Muscle proteolysis was 
found to be significantly increased. 
 
Pathways activated to degrade protein 
 
Recent evidence indicates that the bulk of protein in 
all cells, including muscle, is degraded by the 
ubiquitin-proteasome pathway which requires ATP 
[11]. Membrane proteins, transcription factors as well 
as structural proteins are all degraded by this 
proteolytic pathway. Fortunately, the rate of 
degradation in this pathway is highly regulated.  The 
first type of regulation is that protein that will be 
degraded is conjugated to ubiquitin (Figure 3). 
Ubiquitin is a member of the heat-shock protein 
family that is present in all cells and serves to 
identify which protein should be degraded in the 
proteasome.  A second level of regulation occurs at 
the proteasome, a multisubunit complex of proteins 
forming a ringed complex with a central "tunnel"; 
inside this tunnel, proteolysis occurs. The proteasome 
unfolds the substrate protein, removes ubiquitin and 
directs the protein into the central tunnel where it is 
clipped into small peptides of 7-12 amino acids.  
These small peptides are degraded by cytoplasmic 
peptidases and the amino acids are released from the 
cell.  
Experimentally, the ubiquitin-proteasome pathway in 
muscle has been found to be activated in a number of 
catabolic states including metabolic acidosis, uremia, 
starvation, diabetes, cancer, sepsis, trauma and 
denervation [11]. In each of these conditions, the 
increased activity of the pathway is accompanied by 
high levels of mRNAs encoding ubiquitin and at least 
some subunits of the large proteasome complex. The 
increase in levels of mRNAs is due in part to 
stimulation of transcription of the genes, at least in 
uremia and diabetes [11]. Because the ubiquitin-
proteasome pathway is activated in many illnesses, 
the signal stimulating the transcription of these genes 
is under intensive investigation. 
Regarding therapy of ARF, there are inhibitors of the 
ubiquitin-proteasome pathway that can block the 
excessive muscle protein degradation in isolated 
muscle of rats with ARF. The usefulness of these 
inhibitors in blocking the excessive protein 
degradation in muscle of animals or patients with 
catabolic conditions have not been tested [11]. 
 
Nutritional therapy of ARF patients 
 
The consequences of these metabolic alterations plus 
those from diseases causing ARF determine the type 
and optimal composition of nutritional support 
therapy. The stable patient with uncomplicated ARF 
and minimal to moderate hypercatabolism generally 
does not require any nutritional intervention while 
hypercatabolic patients with dysfunction of organs 
besides the kidney will require nutritional support to 
prevent the loss of lean body mass. Some points 
deserve special consideration: 
First; at what level of renal failure do the various 
metabolic defects become clinically important?  
Clinical studies indicate that changes in lipid and 
carbohydrate metabolism can be measured in 
virtually all patients when the creatinine clearance is 
below 30 ml/min (corresponding to a serum 
creatinine > 3.0 mg/dl).  Likewise, protein balance is 
abnormal (i.e. muscle protein catabolism is high and 
there is impaired protein synthesis when creatinine 
clearance is below 25 ml/min), especially if there is 
acidosis. 
 
 
 
Fig. 3. Schematic drawing of the ubiquitin-proteasome pathway showing that proteins degraded in this pathway are first conjugated with 
ubiquitin in an ATP-dependent reaction. The conjugated protein is recognized, unfolded and degraded to small peptides by the proteasome. 
 
 
 
A second question; is should nutrients be given 
enterally or parenterally? Whenever possible, enteral 
nutrition is preferred. Even if parenteral nutrition is 
needed, some nutrients should be given by the enteral 
route since even small amounts can improve 
intestinal functions, especially the barrier against 
translocation of bacteria through the intestinal wall 
and hence, sepsis [5]. 
The third question; is when should nutritional support 
be initiated? During the acute phase of injury (i.e. 
within the first 24 hours after trauma or surgery - 
known as the "ebb phase") nutrients should be 
withheld. Provision of amino acids or glucose during 
this phase increase oxygen requirements in damaged 
organs, including the kidney, but oxygen supply is 
often limited leading to more tissue injury and further 
impairment of renal function [32]. It is recommended 
that nutritional support should be withheld for 24 
hours after the injury and then given at a low rate to 
ensure optimal nutrient utilization while avoiding 
metabolic derangements. 
 
Energy substrates 
 
How many calories does the patient need?  No patient 
with an acute disease should receive more calories 
than he or she can utilize because excess calories will 
just be stored as fat.  Lipogenesis occurs primarily in 
hepatocytes but unfortunately, the new lipid causes 
fatty infiltration of the liver and impairs hepatic 
function. An excess of calories increases oxygen 
consumption and body temperature (―substrate-indu-
ced thermogenesis‖) while stimulating catecholamine 
secretion (―nutritional stress‖). Oxidation of carbohy-
drates is also associated with an exaggerated release 
of carbon dioxide that aggravates respiratory insuffi-
ciency [5]. Energy expenditure has been measured by 
indirect calorimetry or by dilution techniques using a 
right heart catheter and there is good evidence that 
the energy requirements of an ARF patient with 
sepsis and multiple organ dysfunction syndrome 
rarely exceeds 25 to 30% above basic requirements 
[5]. 
Thus, in 90% of the patients an energy supply of 
130% of the Basal Energy Expenditure (BEE) as 
estimated by the Harris-Benedict equation will be 
sufficient. 
Glucose: Should be the main energy substrate in a 
parenteral nutrition regimen.  It should be supplied at 
a rate that does not exceed the rate of glucose 
oxidation and < 5 g/kg/day, because above this level 
the fraction of glucose converted to fat and the 
amount of CO2 generated increase sharply [33]. This 
occurs because of the glucose intolerance from ARF 
plus factors such as trauma or infections. Even 
though insulin will normalize the blood glucose, it 
will not augment the oxidation of glucose to energy.  
On the other hand, hyperglycemia can stimulate 
protein catabolism or non-enzymatic glycosylation of 
proteins and immunoglobulins [34]. For these 
reasons, at least a fraction of the energy requirement 
should be replaced by lipids. 
 
Lipids: A combination of lipids and glucose as 
energy substrates increases the survival of uremic 
animals.  This combination reflects the pattern of 
endogenous substrates oxidized more closely than 
glucose alone; the body oxidizes fatty acids to 
provide at least 60% of energy expenditure, even if 
glucose is given exclusively. In addition, lipids 
provide structural molecules (membrane 
components) and precursors of prostaglandin 
synthesis.  Lipid emulsions also have a high specific 
energy content and a low osmolality.  Medium-chain 
triglycerides do not offer specific advantages over 
emulsions containing long-chain triglycerides in 
patients with ARF [12]. Most agree that 10% fat 
emulsions should be avoided because the 
phospholipid/triglyceride ratio could result in 
liposome accumulation, especially in the presence of 
impaired lipolytic activity. 
 
Amino acids and protein supply: Activation of 
protein catabolism in ARF along with enhanced 
hepatic conversion of amino acids to glucose is a 
metabolic response that is not suppressed by giving 
glucose or amino acids. Thus, it is impossible to 
achieve nitrogen balance simply by increasing energy 
intake in a catabolic patient with ARF. Moreover, 
any excess of nitrogen intake increases the 
production of urea and other nitrogenous waste 
products and more pronounced negative nitrogen 
balance. 
The relationship between nitrogen intake and protein 
catabolism is "U-shaped": an insufficient amount 
stimulates endogenous protein catabolism but an 
excessive intake results in the surplus of amino acids 
being converted to urea and other waste products.  
Thus, the optimal intake should reduce endogenous 
protein breakdown and urea production to the 
minimum while stimulating protein synthesis. In non-
catabolic patients during the recovery phase of ARF 
but not requiring dialysis therapy, protein requirem-
ents range from 0.6 - 0.8 g kg /day. In patients treated 
by regular renal replacement therapy (daily 
hemodialysis or continuous hemofiltration / hemo-
dialysis) amino acid or protein intake should be 
adjusted to 1.2 g/kg/day [5]. In septic patients it was 
shown that an optimal intake was 1.4 g/kg/day so 
dietary protein or infused amino acids should be 
<1.5g protein/kg/day [11]. 
Since mortality in ARF is correlated with the degree 
of hypercatabolism and since protein catabolism 
cannot be suppressed by conventional nutritional 
strategies, future advances must include methods that 
inhibit protein catabolic pathways [11]. Possibilities 
include growth factors such as human growth 
hormone, epidermal growth factor or insulin-like 
growth factor-I. In rats with ischemic ARF, IGF-I 
improved nitrogen balance but also accelerated 
recovery from renal failure [35].  Preliminary clinical 
investigations have yielded less clear-cut results.  
 
Conclusions 
 
The objectives of nutritional support in patients with 
ARF do not differ from those in other clinical 
situations but there are multiple metabolic alterations 
that complicate the design of nutritional regimens.  
Current nutritional strategies do not correct or 
compensate for hypercatabolism. The identification 
of interventions that suppress the accelerated protein 
breakdown associated with ARF must be developed 
to improve nutritional support and ultimately, 
survival in patients. Since the pathways causing 
catabolism including the ubiquitin-proteasome 
pathway and BCKAD are known, there are targets for 
specific strategies. Growth factors such as human 
growth hormone or insulin-like growth factor-I and 
inhibitors of specific pathways of protein degradation 
present the most promising approach to the solution 
to hypercatabolism in ARF. 
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